Coverage may be limited but is evolving with recent policy adaptations
In the main trial (SURMOUNT-1) of 2,539 participants, adults with obesity or being overweight achieved up to 22.5% average weight loss over 72 weeks on the highest dose of tirzepatide, with lower doses also delivering substantial results
More serious but less common risks include pancreatitis, gallbladder disease, acute kidney injury (often secondary to dehydration from gastrointestinal effects), and hypoglycaemia when used with insulin or sulphonylureas
Resident glial cells become activated, aiding in antigen presentation to T helper cells
Work with your GP or diabetes specialist to implement alternative management strategies before discontinuing treatment
Addressing any nutritional gaps, such as iron or vitamin D deficiency, may reduce symptoms